Anika Therapeutics, Inc.
ANIK
$9.05
$0.688.12%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 123.74M | 126.25M | 129.10M | 95.60M | 98.31M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 123.74M | 126.25M | 129.10M | 95.60M | 98.31M |
| Cost of Revenue | 75.53M | 71.91M | 70.47M | 48.92M | 27.38M |
| Gross Profit | 48.22M | 54.34M | 58.64M | 46.68M | 70.93M |
| SG&A Expenses | 55.57M | 58.96M | 61.12M | 34.21M | 39.93M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 157.22M | 157.36M | 158.43M | 100.13M | 84.85M |
| Operating Income | -33.48M | -31.11M | -29.33M | -4.53M | 13.46M |
| Income Before Tax | -35.41M | -32.66M | -30.70M | -5.46M | 15.11M |
| Income Tax Expenses | 5.60M | 6.25M | 6.20M | 12.73M | 9.96M |
| Earnings from Continuing Operations | -41.01 | -38.90 | -36.90 | -18.19 | 5.16 |
| Earnings from Discontinued Operations | -19.62M | -17.84M | -19.48M | -105.00K | -105.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -60.63M | -56.74M | -56.39M | -97.52M | -74.18M |
| EBIT | -33.48M | -31.11M | -29.33M | -4.53M | 13.46M |
| EBITDA | -26.10M | -23.08M | -20.83M | 5.35M | 24.70M |
| EPS Basic | -4.14 | -3.87 | -3.84 | -6.64 | -5.06 |
| Normalized Basic EPS | -1.35 | -1.23 | -1.14 | -0.09 | 0.68 |
| EPS Diluted | -4.16 | -3.88 | -3.84 | -6.64 | -5.06 |
| Normalized Diluted EPS | -1.35 | -1.23 | -1.14 | -0.09 | 0.68 |
| Average Basic Shares Outstanding | 58.01M | 58.48M | 58.88M | 58.96M | 58.83M |
| Average Diluted Shares Outstanding | 58.21M | 58.54M | 58.95M | 58.98M | 58.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |